Literature DB >> 17965538

Possible involvement of endogenous 5-HT in aggravation of cerulein-induced acute pancreatitis in mice.

Kentaro Hamada1, Masanori Yoshida, Hiroyuki Isayama, Yoshiki Yagi, Shuichi Kanazashi, Yasunari Kashihara, Koji Takeuchi, Isamu Yamaguchi.   

Abstract

The aim of the present study was to elucidate the pathogenic role of endogenous 5-HT in pancreatitis. Injections of cerulein at hourly intervals caused edematous pancreatitis in mice characterized by hyperenzymemia and histological alterations. While the cerulein-induced hyperenzymemia was attenuated in mice pretreated with p-CPA, a 5-HT depletor, it was exaggerated by the preferential 5-HT2A agonist (DOI), but not by the preferential 5-HT2B agonist (BW723C86) or the preferential 5-HT2C agonist (mCPP). Selective 5-HT2A antagonists (risperidone, spiperone, ketanserin, AMI-193, and MDL 11,939) dose-dependently attenuated the hyperenzymemia; and their potency order, excepting that of ketanserin which has considerable affinity at the 5-HT2C receptor as well, paralleled their reported pKi values at the 5-HT2A receptor. Selective 5-HT2B (SB204741) and 5-HT2C (SB242084) antagonists hardly affected the hyperenzymemia. Although the non-selective 5-HT2A/2B/2C antagonists (metergoline, ritanserin, and methysergide) dose-dependently attenuated the hyperenzymemia, they were relatively less potent compared to their high pKi values at the 5-HT2A receptor. In another set of experiments, risperidone, but not SB204741 and SB242084, dose-dependently reversed the cerulein-induced histological alteration of the pancreas (inflammatory cell infiltration). These results suggest that endogenously released 5-HT activates 5-HT2A receptors to aggravate cerulein-induced pancreatitis. We propose that selective 5-HT2A antagonists may provide a new therapy for acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965538     DOI: 10.1254/jphs.fp0071049

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  3 in total

1.  The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.

Authors:  Takeshi Tsujino; Hiroyuki Isayama; Yousuke Nakai; Yukiko Ito; Osamu Togawa; Nobuo Toda; Toshihiko Arizumi; Hirofumi Kogure; Keisuke Yamamoto; Suguru Mizuno; Yoko Yashima; Hiroshi Yagioka; Takashi Sasaki; Saburo Matsubara; Natsuyo Yamamoto; Kenji Hirano; Naoki Sasahira; Minoru Tada; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2012-10-24       Impact factor: 7.527

2.  Impact of Muscarinic M3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study.

Authors:  Yen-Hao Tran; Catharina C M Schuiling-Veninga; Jorieke E H Bergman; Henk Groen; Bob Wilffert
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 5.749

3.  Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment.

Authors:  Murat Pekgöz
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.